CONTEXT THERAPEUTICS
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
CONTEXT THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.contexttherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
31.25 M USD
Technology used in webpage:
Viewport Meta Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Global Site Tag Euro Organization Schema
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Allero Therapeutics
Allero Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Chromis Therapeutics
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company
Cloudbreak Therapeutics
Cloudbreak Therapeutics is a clinical stage biotechnology company
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Halia Therapeutics
Halia is a preclinical-stage biopharmaceutical company.
HighTide Therapeutics
HighTide Therapeutics is a global clinical-stage biopharmaceutical company.
Purple Biotech
Purple Biotech is an innovative biopharmaceutical drug development company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Metera Pharmaceuticals
Metera Pharmaceuticals is a preclinical stage biotechnology company.
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
OncoQuest
OncoQuest is a Edmonton-based biopharmaceutical company.
Aralez Pharmaceuticals
Aralez Pharmaceuticals is a global specialty pharmaceutical company.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
ZSX Medical
ZSX Medical, LLC, is a pre-clinical stage medical device company.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.contexttherapeutics.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.63 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Context Therapeutics"
About — Context Therapeutics
Our Purpose. Our purpose is what weaves us together. It is the single most important reason we come to work each day. We are united by our passion for helping patients with cancer.See details»
Team Bios - Context Therapeutics
She is responsible for all aspects of GMP/GCP/GLP quality for the organization. Erin has more than 15 years’ experience in the pharmaceutical industry in various analytical and quality …See details»
Context Therapeutics - Crunchbase Company Profile & Funding
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor …See details»
Context Therapeutics - LinkedIn
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors.See details»
Committee Composition - Context Therapeutics Inc.
The Investor Relations website contains information about Context Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.See details»
| Context Therapeutics Inc.
The Investor Relations website contains information about Context Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Context Therapeutics Announces FDA Clearance of IND …
May 2, 2024 For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking Statements This press …See details»
Management — Context Therapeutics
Meet our Management TeamSee details»
Investor Relations | Context Therapeutics Inc.
Context is dedicated to developing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. We are building an innovative portfolio of clinical …See details»
Context Therapeutics Inc. (CNTX) Stock Price, News, …
Find the latest Context Therapeutics Inc. (CNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Context Therapeutics Expands Board of Directors
Mar 22, 2021 ONA-XR is a novel, first-in-class complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is …See details»
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody. Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumorsSee details»
Context Therapeutics® Reports First Quarter 2022 Operating and ...
May 11, 2022 For more information, visit www.contexttherapeutics.com. Forward-looking Statements This press release contains “forward-looking statements” that involve substantial …See details»
Contact — Context Therapeutics
Context Therapeutics. 2001 Market Street Suite 3915, Unit 15 Philadelphia, PA 19103. P: 267.225.7416See details»
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 Context Therapeutics Inc. CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody. Acquisition expands Context pipeline with second clinical-stage T cell …See details»
Context Therapeutics Inc. (CNTX) Stock Price, News, Quote
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 …See details»
Context Therapeutics to Participate in Upcoming Investor …
Oct 23, 2024 For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking Statements This press …See details»
News & Media — Context Therapeutics
Kelly Byrnes-Blake, Edward Calamai, Stanley Roberts, and Eric Butz. Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting I Abstract 1288 I November 7-11, 2024See details»
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking Statements This press …See details»